SAN DIEGO, CA--(Marketwire - January 28, 2008) - Lpath, Inc. (OTCBB: LPTN), the category leader in therapeutic agents against bioactive lipids, has successfully humanized its Lpathomab™ monoclonal antibody against lysophospholipid acid (LPA). As a promoter of tumorigenesis and metastasis, LPA is an important bioactive lipid and a well-validated cancer drug target. LPA is also a well-known contributor to neuropathic pain.
